secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001104659-25-024446
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar amends CEO/COO severance, reduces stockholder quorum to one-third
---------------------------------------------------------------------------

- Board on March 12, 2025 approved enhanced severance for CEO and COO upon qualifying termination after a change in control.
- CEO James V. Caruso gets 24 months base salary, target bonus, and benefit continuation.
- COO Jarrod Longcor gets 18 months base salary and benefit continuation.
- On March 11, 2025, Board adopted amended Bylaws reducing stockholder quorum from a majority to one-third of shares.
- Bylaws also revise procedural requirements for stockholder nominations and other business, and align with Delaware law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/0001104659-25-024446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/tm259506d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-024446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer